WO2015061442A1 - Delayed release pharmaceutical compositions of salsalate - Google Patents
Delayed release pharmaceutical compositions of salsalate Download PDFInfo
- Publication number
- WO2015061442A1 WO2015061442A1 PCT/US2014/061760 US2014061760W WO2015061442A1 WO 2015061442 A1 WO2015061442 A1 WO 2015061442A1 US 2014061760 W US2014061760 W US 2014061760W WO 2015061442 A1 WO2015061442 A1 WO 2015061442A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salsalate
- modified release
- pharmaceutical composition
- composition
- release pharmaceutical
- Prior art date
Links
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical group OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 title claims abstract description 404
- 229960000953 salsalate Drugs 0.000 title claims abstract description 202
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 69
- 230000003111 delayed effect Effects 0.000 title description 12
- 239000000203 mixture Substances 0.000 claims abstract description 121
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000008569 process Effects 0.000 claims abstract description 18
- 239000003826 tablet Substances 0.000 claims description 57
- 239000008188 pellet Substances 0.000 claims description 55
- 238000000576 coating method Methods 0.000 claims description 37
- 239000011248 coating agent Substances 0.000 claims description 36
- 239000008187 granular material Substances 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 28
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 28
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 27
- 229920000642 polymer Polymers 0.000 claims description 26
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 25
- 239000002775 capsule Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 17
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 16
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 16
- 229960004889 salicylic acid Drugs 0.000 claims description 15
- 238000004090 dissolution Methods 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 14
- -1 glidants Substances 0.000 claims description 14
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 14
- 230000036470 plasma concentration Effects 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- 239000006172 buffering agent Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000000181 anti-adherent effect Effects 0.000 claims description 5
- 239000003911 antiadherent Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- 229920001800 Shellac Polymers 0.000 claims description 4
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 4
- 229940081735 acetylcellulose Drugs 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 238000009505 enteric coating Methods 0.000 claims description 4
- 239000002702 enteric coating Substances 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 239000004208 shellac Substances 0.000 claims description 4
- 229940113147 shellac Drugs 0.000 claims description 4
- 235000013874 shellac Nutrition 0.000 claims description 4
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000012055 enteric layer Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 239000006068 taste-masking agent Substances 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920003143 Eudragit® FS 30 D Polymers 0.000 claims description 2
- 229920003139 Eudragit® L 100 Polymers 0.000 claims description 2
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims description 2
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 claims description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 2
- UGZICOVULPINFH-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O UGZICOVULPINFH-UHFFFAOYSA-N 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 239000008213 purified water Substances 0.000 description 40
- 239000006185 dispersion Substances 0.000 description 37
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 36
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 36
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 33
- 229960003943 hypromellose Drugs 0.000 description 28
- 229920002785 Croscarmellose sodium Polymers 0.000 description 23
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 23
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 23
- 229960001681 croscarmellose sodium Drugs 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 description 17
- 239000008108 microcrystalline cellulose Substances 0.000 description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 15
- 235000021355 Stearic acid Nutrition 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 12
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 12
- 239000008117 stearic acid Substances 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 239000007912 modified release tablet Substances 0.000 description 6
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 6
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229940126409 proton pump inhibitor Drugs 0.000 description 6
- 239000000612 proton pump inhibitor Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 229940033134 talc Drugs 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920002494 Zein Polymers 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011247 coating layer Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229920003125 hypromellose 2910 Polymers 0.000 description 4
- 229940031672 hypromellose 2910 Drugs 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000008371 vanilla flavor Substances 0.000 description 4
- 239000005019 zein Substances 0.000 description 4
- 229940093612 zein Drugs 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000008387 emulsifying waxe Substances 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 229940068984 polyvinyl alcohol Drugs 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- YVJQWLQBUBZFTE-UHFFFAOYSA-N 2-[2-(2-hydroxybenzoyl)oxybenzoyl]oxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O YVJQWLQBUBZFTE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 244000241235 Citrullus lanatus Species 0.000 description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 244000004281 Eucalyptus maculata Species 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 240000001238 Gaultheria procumbens Species 0.000 description 2
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000220225 Malus Species 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 244000078639 Mentha spicata Species 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 240000009023 Myrrhis odorata Species 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000012550 Pimpinella anisum Nutrition 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 240000001987 Pyrus communis Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229940043237 diethanolamine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 239000008369 fruit flavor Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 159000000011 group IA salts Chemical class 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002346 layers by function Substances 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 235000013913 Ceratonia Nutrition 0.000 description 1
- 241001060815 Ceratonia Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920003098 Methocel™ E5 LV Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 206010070818 Oesophageal irritation Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940043431 ceratonia Drugs 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010013864 duodenitis Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229940048820 edetates Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N gallic acid propyl ester Natural products CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950007395 leminoprazole Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000007896 modified release capsule Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000008388 non-ionic emulsifying wax Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Definitions
- the present invention relates to modified release pharmaceutical compositions comprising salsalate.
- the invention also relates to processes for the preparation of such compositions.
- Salsalate (salicylsalicylic acid; 2-hydroxybenzoic acid 2-carboxyphenyl ester) is a nonsteroidal anti-inflammatory structure of Formula I.
- Paul, Minn. is supplied as a tablet coated with hydroxypropyl methylcellulose and additionally containing magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, starch, talc, and dye (Physician's Desk Reference, 1988, 42, 1678).
- Salsalate is generally non-compressible and shows a wide variety of tableting characteristics depending on the method of manufacture. Salsalate tablets can be difficult to compress and may be subject to internal lamination, which may lead to a catastrophic tablet failure known as capping.
- U.S. Patent No. 5,225,201 discloses a salsalate tablet comprising hydroxypropyl cellulose as a binder substantially uniformly dispersed in the tablet.
- the tablets disclosed have good mechanical strength and exhibit a relatively low incidence of capping and does not require a discrete outer film coating to prevent esophageal irritation.
- the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition releases substantially no drug within the first two hours of its administration.
- the salsalate is the sole active ingredient in the composition.
- the present invention provides a modified release pharmaceutical composition
- a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 100 mg to about 1000 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salsalate with a mean of C ma x less than about 30 ⁇ g/mL, a mean of AUC less than about 60 ⁇ g * hr/mL; and a mean of T max of at least about 2 hours.
- the present invention provides a modified release pharmaceutical composition
- a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 100 mg to about 1000 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salicylic acid with a mean of C max less than about 55 ⁇ g/mL, a mean of AUC less than about 500 ⁇ g * hr/mL; and a mean of T max of at least about 4.5 hours.
- a modified release pharmaceutical composition comprising salsalate, wherein the salsalate is present in an amount of at least 50% by weight of the total composition. In another embodiment the salsalate is present in an amount of at least 70% by weight of the total composition.
- a pharmaceutical composition comprising salsalate, one or more enteric polymers and one or more pharmaceutically acceptable excipients.
- Embodiments of the pharmaceutical composition may include one or more of the following features.
- the pharmaceutically acceptable excipient may include a diluent, a disintegrant, a binder, a stabilizer, a buffering agent, a lubricant, a glidant, an antiadherent, a solubilizer, a sweetener, a flavoring agent, a solvent, and the like.
- the enteric polymer may be mixed and/or granulated with salsalate or is coated over the core containing salsalate.
- a pharmaceutical composition comprising salsalate and one or more pharmaceutically acceptable excipients, wherein the composition further comprises an additional active ingredient.
- the pharmaceutically acceptable excipient may include a diluent, a disintegrant, a binder, a stabilizer, a buffering agent, a lubricant, a glidant, an antiadherent, a solubilizer, a sweetener, a flavoring agent, a solvent, and the like.
- a process for preparing a modified release pharmaceutical composition of salsalate comprising mixing salsalate with one or more enteric polymers and one or more pharmaceutically acceptable excipients; and forming the mixture thus obtained into a pharmaceutical dosage form.
- a process for preparing a modified release pharmaceutical composition of salsalate comprises preparing a core comprising salsalate and one or more pharmaceutically acceptable excipients; and coating the core with a solution/suspension of one or more enteric polymers.
- a modified release pharmaceutical composition comprising salsalate, wherein the composition retains at least 80% of the potency of salsalate in the composition after storage for three months at 40 ° C and 75% relative humidity.
- a modified release pharmaceutical composition comprising salsalate, wherein the composition exhibits an in vitro dissolution profile, when measured in a USP dissolution apparatus type I, at 150 rpm, at a temperature of 37.0 ⁇ 0.5°C in 900 ml of 0.1 N HCI for first two hours followed by in pH 7.4 phosphate buffer, such that at most 10% of salsalate is released in the first two hours and at least 80% of salsalate is released within the next two hours.
- a method for reducing incidences of side effects associated with salsalate administration comprising administering to a subject in need thereof an effective amount of a modified release pharmaceutical composition comprising salsalate, wherein said pharmaceutical composition when administered in a fasted state provides an in-vivo plasma profile for salsalate with a mean of C ma x less than about 30 ⁇ g/mL, a mean of AUC less than about 60 ⁇ g * hr/mL; and a mean of T max of at least about 2 hours.
- a method for providing relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder in a patient in need thereof comprising administering to the patient about 100 mg to about 1000 mg of salsalate in one or more modified release oral dosage forms, wherein the administering step provides an in-vivo plasma profile for salsalate with a mean maximum plasma concentration (C ma x) less than 30 ⁇ g/mL of salsalate, a mean AUC less than about 60 ⁇ g * hr/mL and a mean T max of at least 2 hours to the patient.
- C ma x mean maximum plasma concentration
- a method for providing relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder in a patient in need thereof comprising administering to the patient about 100 mg to about 1000 mg of salsalate in one or more modified release oral dosage forms, wherein at steady state the composition has a fluctuation index about 10-30% lower than a fluctuation index achieved with an immediate-release composition of the salsalate.
- a pharmaceutical composition for modified release comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition provides change in plasma concentration of salsalate as a function of time (dC/dT) over a defined period between 0 to 3 hours after administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over said defined time period, wherein the dC/dT is measured in a single dose human pharmacokinetic study.
- a pharmaceutical composition for modified release comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition provides a change in plasma concentration of salicylic acid as a function of time (dC/dT) over a defined period between 0 to 4 hours after administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over said defined time period, wherein the dC/dT is measured in a single dose human pharmacokinetic study.
- a modified release pharmaceutical composition of salsalate consists of granules of salsalate and one or more pharmaceutically acceptable excipients and an extragranular portion of one or more pharmaceutical excipients that is mixed with the granules and compressed into a tablet that is coated with an optional seal coating layer and then with a modified release coating.
- a modified release pharmaceutical composition of salsalate consists essentially of granules of salsalate and one or more pharmaceutically acceptable excipients and an extragranular portion of one or more pharmaceutical excipients that is mixed with the granules and compressed into a tablet that is coated with an optional seal coating layer and then with a modified release coating to control the release of the salsalate from the tablet.
- the amount of salsalate used in the modified release composition having salsalate granules may be greater than 50%, preferably greater than 70% by weight of the total composition.
- the total weight of the salsalate composition may be between 900 to 1500 mg, if the amount of salsalate used in the composition is about 750 mg.
- the total weight of the 750 mg salsalate composition may be between 900 to 1400 mg, between 900 to 1300 mg, between 900 to 1200 mg or between 900 to 1 100 mg.
- the weight is calculated on the basis of the coated dosage form.
- the total weight of the salsalate composition may be between 550 to 1000 mg, if the amount of salsalate used in the composition is about 500 mg.
- the total weight of the 500 mg salsalate composition may be between 550 to 900 mg, between 550 to 850 mg, between 550 to 800 mg or between 550 to 750 mg. The weight is calculated on the basis of the coated dosage form.
- the use of the term "about" to describe a 750 mg composition of salsalate is intended to convey that a composition labeled with 750 mg of salsalate may have slightly more or less salsalate and still be considered to be a 750 mg composition of the named active ingredient.
- a modified release pharmaceutical composition of salsalate consists of pellets of salsalate and one or more pharmaceutically acceptable excipients that is coated with an optional seal coating layer and then with a modified release coating. The pellets are filled into a capsule.
- a modified release pharmaceutical composition of salsalate consists essentially of pellets of salsalate and one or more pharmaceutical excipients that is coated with an optional seal coating layer and then with a modified release coating to control the release of the salsalate from the pellets.
- the pellets are filled into a capsule.
- the amount of salsalate used in the modified release composition having salsalate pellets may be greater than 50%, preferably greater than 70% by weight of the total composition.
- the total weight of the salsalate composition may be between 900 to 1500 mg, if the amount of salsalate used in the composition is 750 mg. In other embodiments the total weight of the 750 mg salsalate composition may be between 900 to 1400 mg, between 900 to 1300 mg, between 900 to 1200 mg or between 900 to 1 100 mg.
- the weight is calculated on the basis of the coated dosage form.
- the total weight of the salsalate composition may be between 550 to 1000 mg, if the amount of salsalate used in the composition is 500 mg. In other embodiments the total weight of the 500 mg salsalate composition may be between 550 to 900 mg, between 550 to 850 mg, between 550 to 800 mg or between 550 to 750 mg. The weight is calculated on the basis of the coated dosage form.
- a modified release pharmaceutical composition consists of salsalate as the sole active ingredient or consists essentially of salsalate as the active ingredient.
- the modified release pharmaceutical composition will include in addition to the salsalate one or more polymers to control or modify the release of the salsalate from the composition.
- the polymers may be enteric polymers.
- the modified release pharmaceutical composition may consist of a core that includes salsalate and a coating on the core to delay the release of the salsalate from the core.
- the coating may consist essentially of one or more polymers to delay the release of the salsalate from the core based on pH-dependent dissolution of the polymer.
- the coating may be free of zein as the polymer.
- the composition similarly may be free of zein.
- the core may be in the form of a compressed tablet, pellet, extrudate, etc.
- the inventors of the invention have discovered that when salsalate is formulated into a modified release pharmaceutical composition, it prevents irritation of the mucous membranes of the esophagus and the stomach.
- the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition releases substantially no drug within first two hours of its administration.
- the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 100 mg to about 1000 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salsalate with a mean of C max less than about 30 ⁇ g/mL, a mean of AUC less than about 60 ⁇ g * hr/mL; and a mean of T max at least about 2 hours.
- the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 250 mg to about 750 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salsalate with a mean of C ma x less than about 25 ⁇ g/mL, a mean of AUC less than about 50 ⁇ g * hr/mL; and a mean of T max at least about 3 hours.
- the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 500 mg to about 750 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salsalate with a mean of C max less than about 20 ⁇ 9/ ⁇ _, a mean of AUC less than about 45 ⁇ 9 * ⁇ / ⁇ _; and a mean of T max at least about 4 hours.
- the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 100 mg to about 1000 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salicylic acid with a mean of C ma x less than about 55 ⁇ g/mL, a mean of AUC less than about 500 ⁇ g * hr/mL; and a mean of T max at least about 4.5 hours.
- the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 250 mg to about 750 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salicylic acid with a mean of C ma x less than about 40 ⁇ g/mL, a mean of AUC less than about 475 ⁇ g * hr/mL; and a mean of T max at least about 6 hours.
- the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 500 mg to about 750 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salicylic acid with a mean of C max less than about 35 ⁇ g/mL, a mean of AUC less than about 450 ⁇ g * hr/mL; and a mean of T max at least about 7 hours.
- the term "salsalate” used throughout the specification refers to not only salsalate per se, but also its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof.
- the amount of salsalate used in the present invention is in the range less than or equal to 3000 mg/day in a single or divided doses.
- the amount of salsalate used in the composition may be greater than 50%, preferably greater than 70% by weight of the total composition.
- the total weight of the salsalate composition may be between 900 to 1500 mg, if the amount of salsalate used in the composition is 750 mg. In other embodiments the total weight of the 750 mg salsalate composition may be between 900 to 1400 mg, between 900 to 1300 mg, between 900 to 1200 mg or between 900 to 1 100 mg. The weight is calculated on basis of the coated dosage form.
- the total weight of the salsalate composition may be between 550 to 1000 mg, if the amount of salsalate used in the composition is 500 mg. In other embodiments the total weight of the 500 mg salsalate composition may be between 550 to 900 mg, between 550 to 850 mg, between 550 to 800 mg or between 550 to 750 mg. The weight is calculated on basis of the coated dosage form.
- modified release used herein may be understood to include extended release, controlled release, sustained release, delayed release and pulsatile release.
- a “delayed release” composition may be designed to delay the release of the drug for a specified period. Delayed release pharmaceutical compositions of the present invention include those that exhibit a delayed-release, e.g., compositions that only begin releasing the drug after a fixed period of time.
- the delayed release pharmaceutical compositions of the present invention may include the compositions which may release substantially no drug within first two hours and after completion of that the composition may release more than 80% of the drug within next two hours.
- the composition may release less than about 30%, preferably less than 20%, more preferably less than 10% of total drug within one hour after administration.
- the delayed release composition includes an enteric coating, which is a barrier applied to oral drug that prevents release of the drug before it reaches the small intestine.
- Delayed release formulations such as enteric coatings, prevent drugs having an irritant effect on the stomach, such as salsalate, from dissolving in the stomach.
- Such coatings are also used to protect acid-unstable drugs from the stomach's acidic exposure, delivering them instead to a basic pH environment (intestine's pH 5.5 and above) where they do not degrade, and give their desired action.
- the delayed release property of a dosage form may be achieved by using one or more enteric polymers.
- Enteric polymer used in the invention may be selected from hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, hydroxypropyl methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetate phthalate, polyvinyl butyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono- ester copolymer, carboxymethyl ethylcellulose, methyl methacrylate-methacrylic acid copolymer (Eudragit L-100 (methacrylic acid copolymer L) or Eudragit S-100 (methacrylic acid copolymer S)), methacrylic acid-ethyl acrylate copolymer (Eudragit L100-55 (dried methacrylic acid copolymer
- the enteric polymer may be mixed and/or granulated with the drug to prepare final composition.
- the solution or suspension of one or more enteric polymers may be coated on the core containing the drug.
- the core may be prepared as per the knowledge of the skilled artisan.
- the core may be a mixture of drug and excipients or it may be an inert core, coated with a drug layer. There might be an intermediate layer between the drug core and the enteric layer.
- the delayed release property of the dosage form, where present, may be achieved by using press-coating over drug-containing core.
- the press-coat may comprise hydrophilic or hydrophobic rate controlling materials.
- the modified release pharmaceutical composition may further comprise a sustained release component or a controlled release component in a single dose formulation.
- the sustained release or controlled release component may comprise hydrophilic or hydrophobic rate controlling materials.
- Suitable hydrophilic rate controlling materials are selected from, but are not limited to alkyl celluloses such as methyl cellulose; hydroxyalkyl celluloses, for example, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxybutyl cellulose; hydroxyalkyl alkyl celluloses such as hydroxyethyl methyl cellulose and hydroxypropyl methyl cellulose; carboxyalkyl cellulose esters; crosslinked cellulose derivatives such as crosslinked sodium carboxymethyl cellulose; crosslinked polyvinyl pyrrolidone and vinyl acetate (commercially available grade such as Kollidon VA64); polysaccharides such as galactomannans, tragacanth, agar, guar gum, and polyfructans; polyvinyl alcohol; polyethylene glycol, polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate; combinations of polyvinyl alcohol and polyvinylpyr
- Suitable hydrophobic rate controlling materials for coating are selected from, but are not limited to one or more of glyceride (e.g., glyceryl behenate, glyceryl trimyristate, glyceryl trilaurate, glyceryl tristearate, glyceryl monostearate, glyceryl palmitostearate, or glyceryl triacetate), stearic acid, hydrogenated castor oil, a hydrogenated vegetable oil, a water insoluble cellulose (e.g., ethyl cellulose, cellulose acetate, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate butyrate, cellulose acetate propionate, nitrocellulose, cellulose diacetate, or cellulose triacetate), a wax or a wax-like substance (e.g., carnauba wax, cetyl esters wax, beeswax, castor wax, cationic emulsifying wax, cet
- the coating composition may optionally include other excipients, such as binders, lubricants, processing aids, pH buffers, glidants, colorants, and the like, which can be the same or different as those in the core composition, if any.
- excipients such as binders, lubricants, processing aids, pH buffers, glidants, colorants, and the like, which can be the same or different as those in the core composition, if any.
- compositions as described herein may be prepared by processes known to the person having ordinary skill in the art of pharmaceutical technology such as direct compression, wet granulation, dry granulation or melt granulation.
- Suitable final dosage form may comprise one or more of tablets, multilayered tablets, capsules, pellets, granules, spheroids, beads, minitablets in a capsule, pellets in a capsule, granules in a capsule, and powder. Further, the powder or granules can be suspended to give a pharmaceutically acceptable oral suspension.
- the pharmaceutically acceptable excipients may include one or more of diluents, disintegrants, binders, stabilizers, buffering agents, lubricants, glidants, antiadherents, solubilizers, taste masking agents, sweeteners, flavoring agents and solvents.
- Suitable diluents may include one or more of microcrystalline cellulose, starch, dibasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, dextrose, kaolin, magnesium carbonate, magnesium oxide; sugars such as lactose or sucrose; sugar alcohols such as mannitol, sorbitol or erythritol; and mixtures thereof.
- the diluent may be added to increase the bulk volume of the powder to facilitate granulation or compression.
- Suitable disintegrants may include one or more of croscarmellose sodium, crospovidone, sodium starch glycolate, corn starch, potato starch, maize starch and modified starches, calcium silicates, and low substituted hydroxypropylcellulose.
- the amount of disintegrating agent is preferably in the range of 5% to 35% w/w of the composition.
- Suitable binders may include one or more of hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carbomers, dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinyl pyrrolidone, pregelatinized starch, sodium alginate, gums, synthetic resins, and the like.
- Suitable stabilizers may include, especially in the sprinkle oral formulation, alkali- metals and alkaline earth metals, bases of phosphates and organic acid salts and organic amines or mixtures thereof.
- Stabilizers may be selected from sodium citrate, NaCI, K 2 HP0 4 , meglumine, sodium ascorbate, KCI, sodium sulfite, Poloxamer 188/407, polyethylene glycol, glyceryl monooleate, alginic acid, albumin, ammonium alginate, ascorbic acid, ascorbyl palmitate, bentonite, butylated hydroxytoluene, calcium alginate, calcium state, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, ceratonia, colloidal silicon dioxide, cyclodextrins, diethanolamine, edetates, ethylene glycol palmisterate, glycerin monosterate, guargum, magnesium aluminium silicate, lecithin, hypromellose
- Suitable buffering agents may include one or more of ammonia solution, calcium carbonate, calcium phosphate, citric acid, sodium phosphate, diethanol amine, malic acid, monosodium glutamate, phosphoric acid, potassium citrate, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, sodium lactate, triethanol amine, or mixtures thereof or the well-known buffering agents known to a person skilled in the art.
- Suitable lubricants, glidants or anti-adherent agents may include one or more of talc, metallic stearates such as magnesium stearate, calcium stearate, zinc stearate; colloidal silicon dioxide, finely divided silicon dioxide, stearic acid, hydrogenated vegetable oil, glyceryl palmitostearate, glyceryl monostearate, glyceryl behenate, polyethylene glycols, powdered cellulose, starch, sodium stearyl fumarate, sodium benzoate, mineral oil, magnesium trisilicate, kaolin; and mixtures thereof.
- metallic stearates such as magnesium stearate, calcium stearate, zinc stearate
- colloidal silicon dioxide finely divided silicon dioxide
- stearic acid hydrogenated vegetable oil
- glyceryl palmitostearate glyceryl monostearate
- glyceryl behenate polyethylene glycols
- powdered cellulose starch
- lubricant, glidant or anti-tacking agent may be used interchangeably.
- the lubricant, glidant or anti-tacking agent may be present in an amount ranging from 0.1 % to 10 % w/w of the composition.
- Suitable solubilizers may include one or more of sodium lauryl sulphate, polyvinyl pyrrolidone, lactose, mannitol, cyclodextrine or polyethylene glycols.
- Suitable surfactants may include one or more of anionic, cationic, non-ionic or amphoteric surfactants or those known to the person skilled in the art.
- Non-limiting examples of surfactants include polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, commercially available as PluronicTM or PoloxamerTM, ethoxylated cholesterins, commercially available as SolulanTM vitamin derivatives, e. g. vitamin E derivatives such as tocopherol polyethylene glycol succinate (TPGS), sodium dodecylsulfate or sodium lauryl sulfate; a bile acid or salt thereof, for example cholic acid, glycolic acid, or a salt.
- TPGS tocopherol polyethylene glycol succinate
- TPGS sodium dodecylsulfate
- sodium lauryl sulfate a bile acid or salt thereof, for example cholic acid, glycolic acid, or a salt.
- Suitable taste masking agents may include one or more of polymers, sweeteners and flavors. Most preferred polymers may include one or more of cellulose acetate, polymethacrylates, hydroxypropylmethylcellulose, hydroxypropylcellulose, or hydroxylethylcellulose.
- Suitable sweeteners may include one or more of saccharides such as sucrose, dextrose, glucose, maltose, dextrins, D-tagatose, trehalose, dried invert sugar, fructose, levulose, galactose, corn syrup solids, and the like, alone or in combination.
- Other examples of sweeteners include sodium saccharin; aspartame; sugarless sweeteners including polyhydric alcohols such as sorbitol, mannitol, xylitol, glycerol, hydrogenated starch hydrolysates, maltitol, isomaltitol, erythritol, lactitol, and the like, alone or in combination.
- Suitable flavoring agents may include one or more of cinnamon, wintergreen, eucalyptus, spearmint, peppermint, menthol, anise as well as fruit flavors such as apple, pear, peach, strawberry, cherry, apricot, orange, watermelon, banana and the like; bean-derived flavors, such as coffee, cocoa, and the like, or mixtures thereof.
- the pharmaceutical composition of the invention may further comprise another active ingredient, preferably selected from the proton pump inhibitors.
- proton pump inhibitors are used for the prevention and treatment of gastric acid related diseases including, but not limited to, reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer.
- these proton pump inhibitors may be used for the treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable, such as patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, in patients with gastrinomas, and in particular in patients on NSAID therapy.
- proton pump inhibitors or “acid sensitive/unstable proton pump inhibitors” or “PPIs” used throughout the specification refers to agents which inhibit gastric acid secretion by inhibiting H+/K+ ATPase, the enzyme involved in the final step of hydrogen ion production in the parietal cells.
- proto pump inhibitor includes, but is not limited to benzimidazole compounds such as omeprazole, lansoprazole, rabeprazole, pantoprazole and leminoprazole, including isomers, enantiomers and tautomers thereof, and alkaline salts thereof (such as magnesium, sodium).
- a pharmaceutical composition may be prepared by mixing and/or granulating salsalate with one or more enteric polymers and one or more pharmaceutically acceptable excipients; compressing the mixture or granules to form a tablet; and optionally coating the tablet.
- a pharmaceutical composition may be prepared by preparing a core comprising salsalate and one or more pharmaceutically acceptable excipients; optionally coating the core with an intermediate layer; and coating with a layer comprising one or more enteric polymers.
- a pharmaceutical composition may be prepared by preparing an inert core; coating the inert core with a solution / suspension comprising salsalate and one or more pharmaceutically acceptable excipients; coating with one or more enteric layers; and optionally coating with a functional / non-functional layer.
- the non-functional layer may also comprise of flavors like vanilla, cinnamon, wintergreen, eucalyptus, spearmint, peppermint, menthol, anise as well as fruit flavors such as apple, pear, peach, strawberry, cherry, apricot, orange, watermelon, banana and the like; bean-derived flavors, such as coffee, cocoa, and the like, or mixtures thereof.
- a pharmaceutical composition may be prepared by mixing and/or granulating salsalate with one or more pharmaceutically acceptable excipients; filling the mixture or granules into a capsule; and coating the capsule with an enteric coating.
- the pharmaceutical composition according to the invention may retain at least 80% of the potency of salsalate in the composition after storage for three months at 40 ° C and 75% relative humidity.
- the pharmaceutical composition according to the invention exhibits an in vitro dissolution profile, when measured in a USP dissolution apparatus type I, at 150 rpm, at a temperature of 37.0 ⁇ 0.5 ° C in 900 ml of 0.1 N HCI, such that at most 20%, preferably at most 10%, most preferably at most 5% of salsalate is released in first one hour, preferably in first two hours.
- the composition of the present invention releases substantially no drug within first two hours after administration.
- the modified release composition demonstrates good tolerability.
- C max maximum plasma concentration
- AUC area under the curve, a measure of bioavailability
- T max time to maximum plasma concentration
- the control of drug release is particularly desirable for reducing and delaying the peak plasma level while maintaining the extent of drug bioavailability.
- the therapeutic levels are therefore achieved while minimizing debilitating side-effects that are usually associated with immediate release formulations.
- the dosage frequency is reduced to, for example, once or twice daily dosage, thereby improving patient compliance and adherence.
- the side effects including cardiovascular side effects and gastrointestinal side effects may be lessened in severity and frequency through the use of modified release methods that shift the T max to longer times, thereby reducing the dC/dT of the drug.
- Reducing the dC/dT of the drug not only increases T max , but also reduces the drug concentration at T max and reduces the C max /C mea n ratio providing a more constant amount of drug to the subject being treated over a given period of time, enabling increased dosages for appropriate indications.
- C refers to the concentration of an active pharmaceutical ingredient in a biological sample, such as a patient sample (e.g. blood, serum, and cerebrospinal fluid).
- a patient sample e.g. blood, serum, and cerebrospinal fluid.
- T max The time required to reach the maximal concentration (C ma x") in a particular patient sample type is referred to as the "T max ".
- the change in concentration is termed “dC” and the change over a prescribed time is "dC/dT”.
- substantially constant with respect to the serum level of active moiety or moieties means that the serum profile after administration of the controlled release formulation does essentially not exhibit any substantial peak values. This may also be expressed mathematically by reference to the "fluctuation index" (Fl) for the serum concentration of (unbound) active moiety (or sum of active moieties when relevant), where the fluctuation index Fl is calculated as:
- the modified release composition according to the present invention at steady state has a fluctuation index about 10-30% lower than a fluctuation index achieved with an immediate-release composition of the salsalate.
- a method of treating signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders which comprises administering to a human patient in need thereof the modified release pharmaceutical composition of salsalate as per the invention.
- Example 1 Modified release tablets of salsalate (750 mg)
- Salsalate, microcrystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose in purified water.
- the granules were dried and mixed with croscarmellose sodium and colloidal silicon dioxide.
- the granules were lubricated with stearic acid.
- the lubricated mixture was compressed to provide tablets.
- the tablets were seal coated with a dispersion of hypromellose in purified water.
- the coated tablets were again coated with a dispersion of acrylic acid copolymer.
- Buffer Phase 0.25 M pH 7.4 Phosphate Buffer/900 m L/ Apparatus l(Basket)/150 RPM
- Example 2 Modified release tablets of salsalate (750 mg)
- Salsalate, micro-crystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose in purified water.
- the granules were dried and mixed with croscarmellose sodium and colloidal silicon dioxide.
- the granules were lubricated with stearic acid.
- the lubricated mixture was compressed to provide tablets.
- the tablets were seal coated with a dispersion of hypromellose in purified water.
- the coated tablets were again coated with a dispersion of HPMC phthalate.
- Buffer Phase 0.25 M pH 7.4 Phosphate Buffer/900 mL/ Apparatus l(Basket)/150 RPM
- the tablets of salsalate as per Example 2 were administered to healthy human volunteers in the form of tablets that contain 750 mg of salsalate each. These modified release compositions were administered to humans after a fasting period of at least about 8 hours.
- the blood samples were collected from each volunteer before administration and at several time points after administration (e.g., at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours).
- the plasma samples from each volunteer were assayed for salsalate and salicylic acid quantification using a validated method.
- Example 2 provided pharmacokinetic (PK) parameters substantially as shown in the below mentioned Table. These PK parameters are expressed as geometric mean (geometric CV %).
- Example 3 Modified release tablets of salsalate (750 mq)
- Salsalate, microcrystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose in purified water.
- the granules were dried and mixed with croscarmellose sodium and colloidal silicon dioxide.
- the granules were lubricated with stearic acid.
- the lubricated mixture was compressed to provide tablets.
- the tablets were seal coated with a dispersion of hypromellose and polyethylene glycol in purified water and ethanol.
- the coated tablets were then functionally coated with a dispersion of HPMC phthalate and polyethylene glycol in purified water and ethanol.
- the coated tablets were then coated with a flavor coating of Opadry white and vanilla flavor in purified water.
- Buffer Phase 0.25 M pH 7.4 Phosphate Buffer/900 m L/ Apparatus l(Basket)/150 RPM
- Example 4 Modified release capsules of salsalate (500 mq)
- Salsalate, microcrystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose and glycerin in purified water.
- the wet granules were extruded and spheronized to provide wet pellets. These pellets were dried and were seal coated with a dispersion of hypromellose in purified water. The coated pellets were again coated with a dispersion of acrylic acid copolymer. The final coated pellets were sized and filled into the capsules.
- Buffer Phase 0.25 M pH 7.4 Phosphate Buffer/900 m L/ Apparatus I (Basket)/150 RPM
- Example 5 Modified release tablets of salsalate (500 mg)
- Salsalate, microcrystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose in purified water.
- the granules were dried and mixed with croscarmellose sodium and colloidal silicon dioxide.
- the granules were lubricated with stearic acid.
- the lubricated mixture was compressed to provide tablets.
- the tablets were seal coated with a dispersion of hypromellose in purified water.
- the coated tablets were again coated with a dispersion of HPMCP.
- the tablets were then coated with a flavor coat containing vanilla flavor.
- Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the granules are extruded and spheronized to yield pellets.
- the MR1 pellets are dried to provide immediate release pellets of salsalate.
- MR2 component
- Salsalate, micro-crystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the granules are extruded and spheronized to yield pellets.
- the pellets are dried and seal coated with a dispersion of hypromellose in purified water.
- the coated MR2 pellets are coated with a dispersion of methacrylic acid copolymer to provide modified release pellets of salsalate.
- the MR1 pellets and MR2 pellets are mixed together along with micronized talc and filled in appropriate sized capsules.
- the capsules may be further coated with a modified release coating.
- Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the granules are extruded and spheronized to yield pellets.
- the pellets are dried and seal coated with a dispersion of hypromellose in purified water.
- the coated MR1 pellets are coated with a dispersion of methacrylic acid copolymer to provide modified release pellets of salsalate.
- Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the MR2 granules are dried to provide immediate release granules of salsalate.
- the MR1 pellets and MR2 granules are mixed together along with stearic acid and compressed using appropriate tooling to yield tablets. These tablets are then film coated.
- the tablets may be further coated with a modified release coating.
- Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the granules are extruded and spheronized to yield pellets.
- the MR1 pellets are dried to provide immediate release pellets of salsalate.
- Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the granules are extruded and spheronized to yield pellets.
- the pellets are dried and seal coated with a dispersion of hypromellose in purified water.
- the coated MR2 pellets are coated with a dispersion of methacrylic acid copolymer to provide modified release pellets of salsalate.
- Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the granules are extruded and spheronized to yield pellets.
- the pellets are dried and seal coated with a dispersion of hypromellose in purified water.
- the coated MR3 pellets are coated with a dispersion of a different methacrylic acid copolymer than used in the MR2 component to provide modified release pellets of salsalate with a different release profile than of the MR2 pellets.
- the MR1 pellets, MR2 pellets and MR3 pellets are mixed together along with micronized talc and filled in appropriate sized capsules.
- the capsules may be coated with a modified release coating.
- Example 10
- Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the granules are extruded and spheronized to yield pellets.
- the pellets are dried and seal coated with a dispersion of hypromellose in purified water.
- the coated MR1 pellets are coated with a dispersion of methacrylic acid copolymer to provide modified release pellets of salsalate.
- Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the granules are extruded and spheronized to yield pellets.
- the pellets are dried and seal coated with a dispersion of hypromellose in purified water.
- the coated MR2 pellets are coated with a dispersion of different type of methacrylic acid copolymer than used in the MR1 pellets to provide modified release pellets of salsalate with a different release profile than that of the MR1 pellets.
- Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water.
- the granules are dried to provide immediate release MR3 granules of salsalate.
- the MR1 pellets, MR2 pellets and MR3 granules are mixed together along with stearic acid and compressed using appropriate tooling to yield tablets. These tablets are film coated. In an alternative embodiment to Example 9, the tablets may be further coated with a modified release coating.
- Trnax* (hr) 5.50 (3.50, 9.00) 4.50 (3.00, 6.00)
- the mean Cmax is decreased by 25% and both mean AUCo-t and AUCo-inf is decreased by approximately 26% in the modified release formulation.
- the median time-to-peak concentration (Tmax) is also delayed by 1 .00 hour in the modified release formulation as compared to the immediate release formulation (5.50 hours versus 4.50 hours).
- the mean half life of the immediate release and modified release formulations are very similar for salicylic acid.
- the composition provides a change in plasma concentration of salsalate as a function of time (dC/dT) over a defined period between 0 to 3 hours after administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over the defined time period.
- dC/dT Calculation-Salicylic Acid
- the composition provides a change in plasma concentration of salicylic acid as a function of time (dC/dT) over a defined period between 0 to 4 hours after administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over the defined time period.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to modified release pharmaceutical compositions comprising salsalate. The invention also relates to processes for the preparation of such compositions.
Description
MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF SALSALATE
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to US Provisional Patent Application No. 61 /894,277, filed on October 22, 2013. The contents of each of these applications are incorporated herein in their entirety by reference.
FIELD OF THE INVENTION
The present invention relates to modified release pharmaceutical compositions comprising salsalate. The invention also relates to processes for the preparation of such compositions.
BACKGROUND OF THE INVENTION
Salsalate (salicylsalicylic acid; 2-hydroxybenzoic acid 2-carboxyphenyl ester) is a nonsteroidal anti-inflammatory structure of Formula I.
[Formula 1 ]
An article published in Clinical Therapeutics, 1984; 6(4): 388-403 discloses treatment of arthritis with 3 grams of salsalate daily (two 750-mg tablets twice daily) for 15 days. The incidence of side effects experienced with previous therapy was reduced during salsalate administration. Patient compliance with the regimen was greater. The findings show salsalate to be effective and safe in ameliorating the symptoms of arthritic disease. The convenient twice-daily dosage regimen makes this drug particularly suitable for chronic use.
A study shows that salsalate produced a comparable clinical improvement to that with aspirin, and similar serum salicylate levels in patients with osteoarthrosis of the hip or knee. Salsalate, however, was significantly superior to aspirin with regard to side-effects and faecal occult blood loss {Current Medicinal Research and Opinion 1978; 5(6):450-3).
Salsalate has a very unpleasant taste and causes irritation of the mucous membranes of the esophagus. Known salsalate tablets overcome this problem by either film coating or by including excipients in an amount great enough to mask the taste and irritation. For example, DISALCID™ (commercially available from Riker Laboratories, Inc., St. Paul, Minn.) is supplied as a tablet coated with hydroxypropyl methylcellulose and additionally containing magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, starch, talc, and dye (Physician's Desk Reference, 1988, 42, 1678).
Salsalate is generally non-compressible and shows a wide variety of tableting characteristics depending on the method of manufacture. Salsalate tablets can be difficult to compress and may be subject to internal lamination, which may lead to a catastrophic tablet failure known as capping.
U.S. Patent No. 5,225,201 discloses a salsalate tablet comprising hydroxypropyl cellulose as a binder substantially uniformly dispersed in the tablet. The tablets disclosed have good mechanical strength and exhibit a relatively low incidence of capping and does not require a discrete outer film coating to prevent esophageal irritation.
There is still a need for alternate pharmaceutical compositions of salsalate which can reduce irritation of the mucous membranes of the esophagus and the stomach after administration to the patients.
SUMMARY OF THE INVENTION
In one general aspect, the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition releases substantially no drug within the first two hours of its administration. In one embodiment of this general aspect, the salsalate is the sole active ingredient in the composition.
In another general aspect, the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable
salt thereof, wherein the composition comprises about 100 mg to about 1000 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salsalate with a mean of Cmax less than about 30 μg/mL, a mean of AUC less than about 60 μg*hr/mL; and a mean of Tmax of at least about 2 hours.
In another general aspect, the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 100 mg to about 1000 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salicylic acid with a mean of Cmax less than about 55 μg/mL, a mean of AUC less than about 500 μg*hr/mL; and a mean of Tmax of at least about 4.5 hours.
In another general aspect, there is provided a modified release pharmaceutical composition comprising salsalate, wherein the salsalate is present in an amount of at least 50% by weight of the total composition. In another embodiment the salsalate is present in an amount of at least 70% by weight of the total composition.
In another general aspect, there is provided a pharmaceutical composition comprising salsalate, one or more enteric polymers and one or more pharmaceutically acceptable excipients.
Embodiments of the pharmaceutical composition may include one or more of the following features. For example, the pharmaceutically acceptable excipient may include a diluent, a disintegrant, a binder, a stabilizer, a buffering agent, a lubricant, a glidant, an antiadherent, a solubilizer, a sweetener, a flavoring agent, a solvent, and the like.
The enteric polymer may be mixed and/or granulated with salsalate or is coated over the core containing salsalate.
In another aspect, there is provided a pharmaceutical composition comprising salsalate and one or more pharmaceutically acceptable excipients, wherein the composition further comprises an additional active ingredient.
Embodiments of the pharmaceutical composition may include one or more of the following features. For example, the pharmaceutically acceptable excipient may include a diluent, a disintegrant, a binder, a stabilizer, a buffering agent, a lubricant, a glidant, an antiadherent, a solubilizer, a sweetener, a flavoring agent, a solvent, and the like.
In another general aspect, there is provided a process for preparing a modified release pharmaceutical composition of salsalate, wherein the process comprises mixing salsalate with one or more enteric polymers and one or more pharmaceutically acceptable excipients; and forming the mixture thus obtained into a pharmaceutical dosage form.
In another general aspect, there is provided a process for preparing a modified release pharmaceutical composition of salsalate, wherein the process comprises preparing a core comprising salsalate and one or more pharmaceutically acceptable excipients; and coating the core with a solution/suspension of one or more enteric polymers.
In another general aspect, there is provided a modified release pharmaceutical composition comprising salsalate, wherein the composition retains at least 80% of the potency of salsalate in the composition after storage for three months at 40°C and 75% relative humidity.
In another general aspect, there is provided a modified release pharmaceutical composition comprising salsalate, wherein the composition exhibits an in vitro dissolution profile, when measured in a USP dissolution apparatus type I, at 150 rpm, at a temperature of 37.0 ± 0.5°C in 900 ml of 0.1 N HCI for first two hours followed by in pH 7.4 phosphate buffer, such that at most 10% of salsalate is released in the first two hours and at least 80% of salsalate is released within the next two hours.
In another general aspect, there is provided a method for reducing incidences of side effects associated with salsalate administration comprising administering to a subject in need thereof an effective amount of a modified release pharmaceutical
composition comprising salsalate, wherein said pharmaceutical composition when administered in a fasted state provides an in-vivo plasma profile for salsalate with a mean of Cmax less than about 30 μg/mL, a mean of AUC less than about 60 μg*hr/mL; and a mean of Tmax of at least about 2 hours.
In still another general aspect, there is provided a method for providing relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder in a patient in need thereof, comprising administering to the patient about 100 mg to about 1000 mg of salsalate in one or more modified release oral dosage forms, wherein the administering step provides an in-vivo plasma profile for salsalate with a mean maximum plasma concentration (Cmax) less than 30 μg/mL of salsalate, a mean AUC less than about 60 μg*hr/mL and a mean Tmax of at least 2 hours to the patient.
In another general aspect, there is provided a method for providing relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder in a patient in need thereof, comprising administering to the patient about 100 mg to about 1000 mg of salsalate in one or more modified release oral dosage forms, wherein at steady state the composition has a fluctuation index about 10-30% lower than a fluctuation index achieved with an immediate-release composition of the salsalate.
In further general aspect, there is provided a pharmaceutical composition for modified release comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition provides change in plasma concentration of salsalate as a function of time (dC/dT) over a defined period between 0 to 3 hours after administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over said defined time period, wherein the dC/dT is measured in a single dose human pharmacokinetic study.
In a further general aspect, there is provided a pharmaceutical composition for modified release comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition provides a change in plasma concentration of salicylic acid as a function of time (dC/dT) over a defined period between 0 to 4 hours after
administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over said defined time period, wherein the dC/dT is measured in a single dose human pharmacokinetic study.
In another general aspect, a modified release pharmaceutical composition of salsalate consists of granules of salsalate and one or more pharmaceutically acceptable excipients and an extragranular portion of one or more pharmaceutical excipients that is mixed with the granules and compressed into a tablet that is coated with an optional seal coating layer and then with a modified release coating.
In another general aspect, a modified release pharmaceutical composition of salsalate consists essentially of granules of salsalate and one or more pharmaceutically acceptable excipients and an extragranular portion of one or more pharmaceutical excipients that is mixed with the granules and compressed into a tablet that is coated with an optional seal coating layer and then with a modified release coating to control the release of the salsalate from the tablet.
The amount of salsalate used in the modified release composition having salsalate granules may be greater than 50%, preferably greater than 70% by weight of the total composition. The total weight of the salsalate composition may be between 900 to 1500 mg, if the amount of salsalate used in the composition is about 750 mg. In other embodiments the total weight of the 750 mg salsalate composition may be between 900 to 1400 mg, between 900 to 1300 mg, between 900 to 1200 mg or between 900 to 1 100 mg. The weight is calculated on the basis of the coated dosage form. The total weight of the salsalate composition may be between 550 to 1000 mg, if the amount of salsalate used in the composition is about 500 mg. In other embodiments the total weight of the 500 mg salsalate composition may be between 550 to 900 mg, between 550 to 850 mg, between 550 to 800 mg or between 550 to 750 mg. The weight is calculated on the basis of the coated dosage form. The use of the term "about" to describe a 750 mg composition of salsalate is intended to convey that a composition labeled with 750 mg of salsalate may have slightly more or less salsalate and still be considered to be a 750 mg composition of the named active ingredient.
In another general aspect, a modified release pharmaceutical composition of salsalate consists of pellets of salsalate and one or more pharmaceutically acceptable excipients that is coated with an optional seal coating layer and then with a modified release coating. The pellets are filled into a capsule.
In another general aspect, a modified release pharmaceutical composition of salsalate consists essentially of pellets of salsalate and one or more pharmaceutical excipients that is coated with an optional seal coating layer and then with a modified release coating to control the release of the salsalate from the pellets. The pellets are filled into a capsule.
The amount of salsalate used in the modified release composition having salsalate pellets may be greater than 50%, preferably greater than 70% by weight of the total composition. The total weight of the salsalate composition may be between 900 to 1500 mg, if the amount of salsalate used in the composition is 750 mg. In other embodiments the total weight of the 750 mg salsalate composition may be between 900 to 1400 mg, between 900 to 1300 mg, between 900 to 1200 mg or between 900 to 1 100 mg. The weight is calculated on the basis of the coated dosage form. The total weight of the salsalate composition may be between 550 to 1000 mg, if the amount of salsalate used in the composition is 500 mg. In other embodiments the total weight of the 500 mg salsalate composition may be between 550 to 900 mg, between 550 to 850 mg, between 550 to 800 mg or between 550 to 750 mg. The weight is calculated on the basis of the coated dosage form.
In another general aspect, a modified release pharmaceutical composition consists of salsalate as the sole active ingredient or consists essentially of salsalate as the active ingredient. The modified release pharmaceutical composition will include in addition to the salsalate one or more polymers to control or modify the release of the salsalate from the composition. The polymers may be enteric polymers. The modified release pharmaceutical composition may consist of a core that includes salsalate and a coating on the core to delay the release of the salsalate from the core. The coating may consist essentially of one or more polymers to delay the release of the salsalate from the core based on pH-dependent dissolution of the polymer. The coating may be free of zein as the polymer. The composition similarly
may be free of zein. The core may be in the form of a compressed tablet, pellet, extrudate, etc.
The details of one or more embodiments of the invention are set forth in the description below. Other features, objects and advantages of the invention will be apparent from the description.
DETAILED DESCRIPTION OF THE INVENTION
The inventors of the invention have discovered that when salsalate is formulated into a modified release pharmaceutical composition, it prevents irritation of the mucous membranes of the esophagus and the stomach.
The present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition releases substantially no drug within first two hours of its administration.
The present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 100 mg to about 1000 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salsalate with a mean of Cmax less than about 30 μg/mL, a mean of AUC less than about 60 μg*hr/mL; and a mean of Tmax at least about 2 hours.
In some embodiments, the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 250 mg to about 750 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salsalate with a mean of Cmax less than about 25 μg/mL, a mean of AUC less than about 50 μg*hr/mL; and a mean of Tmax at least about 3 hours.
In some embodiments, the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 500 mg to about 750 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile
for salsalate with a mean of Cmax less than about 20 μ9/ιτιΙ_, a mean of AUC less than about 45 μ9*ΙΐΓ/ιτιΙ_; and a mean of Tmax at least about 4 hours.
The present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 100 mg to about 1000 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salicylic acid with a mean of Cmax less than about 55 μg/mL, a mean of AUC less than about 500 μg*hr/mL; and a mean of Tmax at least about 4.5 hours.
In some embodiments, the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 250 mg to about 750 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salicylic acid with a mean of Cmax less than about 40 μg/mL, a mean of AUC less than about 475 μg*hr/mL; and a mean of Tmax at least about 6 hours.
In some embodiments, the present invention provides a modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition comprises about 500 mg to about 750 mg of salsalate and when administered in a fasted state provides an in-vivo plasma profile for salicylic acid with a mean of Cmax less than about 35 μg/mL, a mean of AUC less than about 450 μg*hr/mL; and a mean of Tmax at least about 7 hours.
The term "salsalate" used throughout the specification refers to not only salsalate per se, but also its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof. The amount of salsalate used in the present invention is in the range less than or equal to 3000 mg/day in a single or divided doses. The amount of salsalate used in the composition may be greater than 50%, preferably greater than 70% by weight of the total composition.
The total weight of the salsalate composition may be between 900 to 1500 mg, if the amount of salsalate used in the composition is 750 mg. In other embodiments the total weight of the 750 mg salsalate composition may be between 900 to 1400 mg, between 900 to 1300 mg, between 900 to 1200 mg or between 900 to 1 100 mg. The weight is calculated on basis of the coated dosage form.
The total weight of the salsalate composition may be between 550 to 1000 mg, if the amount of salsalate used in the composition is 500 mg. In other embodiments the total weight of the 500 mg salsalate composition may be between 550 to 900 mg, between 550 to 850 mg, between 550 to 800 mg or between 550 to 750 mg. The weight is calculated on basis of the coated dosage form.
The term "modified release" used herein may be understood to include extended release, controlled release, sustained release, delayed release and pulsatile release. A "delayed release" composition may be designed to delay the release of the drug for a specified period. Delayed release pharmaceutical compositions of the present invention include those that exhibit a delayed-release, e.g., compositions that only begin releasing the drug after a fixed period of time. The delayed release pharmaceutical compositions of the present invention may include the compositions which may release substantially no drug within first two hours and after completion of that the composition may release more than 80% of the drug within next two hours. The composition may release less than about 30%, preferably less than 20%, more preferably less than 10% of total drug within one hour after administration. In some embodiments, the delayed release composition includes an enteric coating, which is a barrier applied to oral drug that prevents release of the drug before it reaches the small intestine. Delayed release formulations, such as enteric coatings, prevent drugs having an irritant effect on the stomach, such as salsalate, from dissolving in the stomach. Such coatings are also used to protect acid-unstable drugs from the stomach's acidic exposure, delivering them instead to a basic pH environment (intestine's pH 5.5 and above) where they do not degrade, and give their desired action.
The delayed release property of a dosage form may be achieved by using one or more enteric polymers. "Enteric polymer" used in the invention may be selected from
hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, hydroxypropyl methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetate phthalate, polyvinyl butyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono- ester copolymer, carboxymethyl ethylcellulose, methyl methacrylate-methacrylic acid copolymer (Eudragit L-100 (methacrylic acid copolymer L) or Eudragit S-100 (methacrylic acid copolymer S)), methacrylic acid-ethyl acrylate copolymer (Eudragit L100-55 (dried methacrylic acid copolymer LD) or Eudragit L30D-55 (methacrylic acid copolymer LD)), methacrylic acid-methyl acrylate-methyl methacrylate copolymer (Eudragit FS30D), hydroxypropyl cellulose acetate succinate (HPMCAS) and shellac.
In some embodiments, the enteric polymer may be mixed and/or granulated with the drug to prepare final composition. Alternatively, the solution or suspension of one or more enteric polymers may be coated on the core containing the drug. The core may be prepared as per the knowledge of the skilled artisan. The core may be a mixture of drug and excipients or it may be an inert core, coated with a drug layer. There might be an intermediate layer between the drug core and the enteric layer.
The delayed release property of the dosage form, where present, may be achieved by using press-coating over drug-containing core. The press-coat may comprise hydrophilic or hydrophobic rate controlling materials.
In specific embodiments, the modified release pharmaceutical composition may further comprise a sustained release component or a controlled release component in a single dose formulation. The sustained release or controlled release component may comprise hydrophilic or hydrophobic rate controlling materials.
Suitable hydrophilic rate controlling materials are selected from, but are not limited to alkyl celluloses such as methyl cellulose; hydroxyalkyl celluloses, for example, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxybutyl cellulose; hydroxyalkyl alkyl celluloses such as hydroxyethyl methyl cellulose and hydroxypropyl methyl cellulose; carboxyalkyl cellulose esters; crosslinked cellulose derivatives such as crosslinked sodium carboxymethyl
cellulose; crosslinked polyvinyl pyrrolidone and vinyl acetate (commercially available grade such as Kollidon VA64); polysaccharides such as galactomannans, tragacanth, agar, guar gum, and polyfructans; polyvinyl alcohol; polyethylene glycol, polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate; combinations of polyvinyl alcohol and polyvinylpyrrolidone; and polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide.
Suitable hydrophobic rate controlling materials for coating are selected from, but are not limited to one or more of glyceride (e.g., glyceryl behenate, glyceryl trimyristate, glyceryl trilaurate, glyceryl tristearate, glyceryl monostearate, glyceryl palmitostearate, or glyceryl triacetate), stearic acid, hydrogenated castor oil, a hydrogenated vegetable oil, a water insoluble cellulose (e.g., ethyl cellulose, cellulose acetate, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate butyrate, cellulose acetate propionate, nitrocellulose, cellulose diacetate, or cellulose triacetate), a wax or a wax-like substance (e.g., carnauba wax, cetyl esters wax, beeswax, castor wax, cationic emulsifying wax, cetrimide emulsifying wax, an emulsifying wax, microcrystalline wax, a nonionic wax, a nonionic emulsifying wax, paraffin, petroleum wax, petroleum ceresin wax, spermaceti wax, white wax, or yellow wax), a fat, an oil, a fatty acid, an emulsifier, a modified starch, a fatty alcohol, a protein (e.g., zein), shellac, or a polymer (e.g., a polyolefin, a polyurethane, a polyvinylchloride, a polyvinyl acetate, an acrylic acid polymer, a methacrylic acid polymer); cetostearyl alcohol, stearyl alcohol, and the like.
The coating composition may optionally include other excipients, such as binders, lubricants, processing aids, pH buffers, glidants, colorants, and the like, which can be the same or different as those in the core composition, if any.
The pharmaceutical compositions as described herein may be prepared by processes known to the person having ordinary skill in the art of pharmaceutical technology such as direct compression, wet granulation, dry granulation or melt granulation.
Suitable final dosage form may comprise one or more of tablets, multilayered tablets, capsules, pellets, granules, spheroids, beads, minitablets in a capsule, pellets in a capsule, granules in a capsule, and powder. Further, the powder or granules can be suspended to give a pharmaceutically acceptable oral suspension.
The pharmaceutically acceptable excipients may include one or more of diluents, disintegrants, binders, stabilizers, buffering agents, lubricants, glidants, antiadherents, solubilizers, taste masking agents, sweeteners, flavoring agents and solvents.
Suitable diluents may include one or more of microcrystalline cellulose, starch, dibasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, dextrose, kaolin, magnesium carbonate, magnesium oxide; sugars such as lactose or sucrose; sugar alcohols such as mannitol, sorbitol or erythritol; and mixtures thereof. The diluent may be added to increase the bulk volume of the powder to facilitate granulation or compression.
Suitable disintegrants may include one or more of croscarmellose sodium, crospovidone, sodium starch glycolate, corn starch, potato starch, maize starch and modified starches, calcium silicates, and low substituted hydroxypropylcellulose. The amount of disintegrating agent is preferably in the range of 5% to 35% w/w of the composition.
Suitable binders may include one or more of hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carbomers, dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinyl pyrrolidone, pregelatinized starch, sodium alginate, gums, synthetic resins, and the like.
Suitable stabilizers may include, especially in the sprinkle oral formulation, alkali- metals and alkaline earth metals, bases of phosphates and organic acid salts and organic amines or mixtures thereof. Stabilizers may be selected from sodium citrate, NaCI, K2HP04, meglumine, sodium ascorbate, KCI, sodium sulfite, Poloxamer 188/407, polyethylene glycol, glyceryl monooleate, alginic acid, albumin, ammonium alginate, ascorbic acid, ascorbyl palmitate, bentonite, butylated hydroxytoluene,
calcium alginate, calcium state, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, ceratonia, colloidal silicon dioxide, cyclodextrins, diethanolamine, edetates, ethylene glycol palmisterate, glycerin monosterate, guargum, magnesium aluminium silicate, lecithin, hypromellose, hydroxypropyl cellulose, polacrilin potassium, pectin, poloxamer, polyvinyl alcohol, propyl gallate, propylene glycol, xylitol, zinc acetate, raffinose, sodium borate, trehalose, propylene glycol alginate, sulfobutylether beta-cyclo dextrin, or mixtures thereof or the well-known stabilizers known to a person skilled in the art.
Suitable buffering agents may include one or more of ammonia solution, calcium carbonate, calcium phosphate, citric acid, sodium phosphate, diethanol amine, malic acid, monosodium glutamate, phosphoric acid, potassium citrate, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, sodium lactate, triethanol amine, or mixtures thereof or the well-known buffering agents known to a person skilled in the art.
Suitable lubricants, glidants or anti-adherent agents may include one or more of talc, metallic stearates such as magnesium stearate, calcium stearate, zinc stearate; colloidal silicon dioxide, finely divided silicon dioxide, stearic acid, hydrogenated vegetable oil, glyceryl palmitostearate, glyceryl monostearate, glyceryl behenate, polyethylene glycols, powdered cellulose, starch, sodium stearyl fumarate, sodium benzoate, mineral oil, magnesium trisilicate, kaolin; and mixtures thereof. It would be appreciated that a person skilled in the art is cognizant of the fact that lubricant, glidant or anti-tacking agent may be used interchangeably. The lubricant, glidant or anti-tacking agent may be present in an amount ranging from 0.1 % to 10 % w/w of the composition.
Suitable solubilizers may include one or more of sodium lauryl sulphate, polyvinyl pyrrolidone, lactose, mannitol, cyclodextrine or polyethylene glycols.
Suitable surfactants may include one or more of anionic, cationic, non-ionic or amphoteric surfactants or those known to the person skilled in the art. Non-limiting examples of surfactants include polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, commercially available as Pluronic™ or Poloxamer™,
ethoxylated cholesterins, commercially available as Solulan™ vitamin derivatives, e. g. vitamin E derivatives such as tocopherol polyethylene glycol succinate (TPGS), sodium dodecylsulfate or sodium lauryl sulfate; a bile acid or salt thereof, for example cholic acid, glycolic acid, or a salt.
Suitable taste masking agents may include one or more of polymers, sweeteners and flavors. Most preferred polymers may include one or more of cellulose acetate, polymethacrylates, hydroxypropylmethylcellulose, hydroxypropylcellulose, or hydroxylethylcellulose.
Suitable sweeteners may include one or more of saccharides such as sucrose, dextrose, glucose, maltose, dextrins, D-tagatose, trehalose, dried invert sugar, fructose, levulose, galactose, corn syrup solids, and the like, alone or in combination. Other examples of sweeteners include sodium saccharin; aspartame; sugarless sweeteners including polyhydric alcohols such as sorbitol, mannitol, xylitol, glycerol, hydrogenated starch hydrolysates, maltitol, isomaltitol, erythritol, lactitol, and the like, alone or in combination.
Suitable flavoring agents may include one or more of cinnamon, wintergreen, eucalyptus, spearmint, peppermint, menthol, anise as well as fruit flavors such as apple, pear, peach, strawberry, cherry, apricot, orange, watermelon, banana and the like; bean-derived flavors, such as coffee, cocoa, and the like, or mixtures thereof.
In some of the embodiments, the pharmaceutical composition of the invention may further comprise another active ingredient, preferably selected from the proton pump inhibitors. Generally, proton pump inhibitors, their single enantiomers or alkaline salts thereof, are used for the prevention and treatment of gastric acid related diseases including, but not limited to, reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Additionally, these proton pump inhibitors may be used for the treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable, such as patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, in patients with gastrinomas, and in particular in patients on NSAID therapy. The term "proton pump inhibitors" or "acid sensitive/unstable proton pump inhibitors" or "PPIs" used throughout the
specification refers to agents which inhibit gastric acid secretion by inhibiting H+/K+ ATPase, the enzyme involved in the final step of hydrogen ion production in the parietal cells. The term "proton pump inhibitor" includes, but is not limited to benzimidazole compounds such as omeprazole, lansoprazole, rabeprazole, pantoprazole and leminoprazole, including isomers, enantiomers and tautomers thereof, and alkaline salts thereof (such as magnesium, sodium).
In one embodiment, a pharmaceutical composition may be prepared by mixing and/or granulating salsalate with one or more enteric polymers and one or more pharmaceutically acceptable excipients; compressing the mixture or granules to form a tablet; and optionally coating the tablet.
In another embodiment, a pharmaceutical composition may be prepared by preparing a core comprising salsalate and one or more pharmaceutically acceptable excipients; optionally coating the core with an intermediate layer; and coating with a layer comprising one or more enteric polymers.
In another embodiment, a pharmaceutical composition may be prepared by preparing an inert core; coating the inert core with a solution / suspension comprising salsalate and one or more pharmaceutically acceptable excipients; coating with one or more enteric layers; and optionally coating with a functional / non-functional layer. The non-functional layer may also comprise of flavors like vanilla, cinnamon, wintergreen, eucalyptus, spearmint, peppermint, menthol, anise as well as fruit flavors such as apple, pear, peach, strawberry, cherry, apricot, orange, watermelon, banana and the like; bean-derived flavors, such as coffee, cocoa, and the like, or mixtures thereof.
In still another embodiment, a pharmaceutical composition may be prepared by mixing and/or granulating salsalate with one or more pharmaceutically acceptable excipients; filling the mixture or granules into a capsule; and coating the capsule with an enteric coating.
The pharmaceutical composition according to the invention may retain at least 80% of the potency of salsalate in the composition after storage for three months at 40°C and 75% relative humidity.
The pharmaceutical composition according to the invention exhibits an in vitro dissolution profile, when measured in a USP dissolution apparatus type I, at 150 rpm, at a temperature of 37.0 ± 0.5 ° C in 900 ml of 0.1 N HCI, such that at most 20%, preferably at most 10%, most preferably at most 5% of salsalate is released in first one hour, preferably in first two hours. In most preferred embodiment of the invention, the composition of the present invention releases substantially no drug within first two hours after administration.
The modified release composition demonstrates good tolerability. Cmax (maximum plasma concentration) is less than about 85% of the immediate release tablets when administered as a single dose. AUC (area under the curve, a measure of bioavailability) is within 75% to 130% of the immediate release tablets administered as a single dose. This range is considered equivalent with respect to overall systemic exposure. Prolonging the time to maximum plasma concentration (Tmax) as compared to immediate release tablet, is related to the release rate of the drug in the use environment. The release rate of the drug depends on many factors, including the composition of the solid dosage forms and the dissolution properties.
The control of drug release is particularly desirable for reducing and delaying the peak plasma level while maintaining the extent of drug bioavailability. The therapeutic levels are therefore achieved while minimizing debilitating side-effects that are usually associated with immediate release formulations. Furthermore, as a result of delay in the time to obtain peak serum or plasma level and the extended period of time at the therapeutically effective serum or plasma level, the dosage frequency is reduced to, for example, once or twice daily dosage, thereby improving patient compliance and adherence. For example, the side effects including cardiovascular side effects and gastrointestinal side effects may be lessened in severity and frequency through the use of modified release methods that shift the Tmax to longer times, thereby reducing the dC/dT of the drug. Reducing the dC/dT of the drug not only increases Tmax, but also reduces the drug concentration at Tmax and
reduces the Cmax/Cmean ratio providing a more constant amount of drug to the subject being treated over a given period of time, enabling increased dosages for appropriate indications.
As used herein, "C" refers to the concentration of an active pharmaceutical ingredient in a biological sample, such as a patient sample (e.g. blood, serum, and cerebrospinal fluid). The time required to reach the maximal concentration ("Cmax") in a particular patient sample type is referred to as the "Tmax". The change in concentration is termed "dC" and the change over a prescribed time is "dC/dT".
The term "substantially constant" with respect to the serum level of active moiety or moieties means that the serum profile after administration of the controlled release formulation does essentially not exhibit any substantial peak values. This may also be expressed mathematically by reference to the "fluctuation index" (Fl) for the serum concentration of (unbound) active moiety (or sum of active moieties when relevant), where the fluctuation index Fl is calculated as:
Fl = (Cmax - Cmin) / AUCT/T wherein Cmax and Cmin are the maximum and minimum concentrations, respectively, of the active moiety, AUCx is the area under the serum concentration profile (concentration vs. time curve), and τ is the length of the dosage interval during the time τ. The modified release composition according to the present invention at steady state has a fluctuation index about 10-30% lower than a fluctuation index achieved with an immediate-release composition of the salsalate.
In other embodiment, there is provided a method of treating signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders which comprises administering to a human patient in need thereof the modified release pharmaceutical composition of salsalate as per the invention.
The invention is further illustrated by the following examples which are provided to be exemplary of the invention and do not limit the scope of the invention. While the
present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Example 1 : Modified release tablets of salsalate (750 mg)
Salsalate, microcrystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose in purified water. The granules were dried and mixed with croscarmellose sodium and colloidal silicon dioxide. The granules were lubricated with stearic acid. The lubricated mixture was compressed to provide tablets. The tablets were seal coated with a dispersion of hypromellose in purified water. The coated tablets were again coated with a dispersion of acrylic acid copolymer.
Dissolution profile for Tablets of Example 1 :
Acid Phase: 0.1 N HCI / 900 ml/Apparatus I (Basket)/150 RPM
Buffer Phase: 0.25 M pH 7.4 Phosphate Buffer/900 m L/ Apparatus l(Basket)/150 RPM
Stability data for Tablets of Example 1 :
Total Impurities
(Excluding Salicylic 0.08% 0.01 % 0.01 % 0.01 % 0.02% Acid & Trisalicylic Acid)
Example 2: Modified release tablets of salsalate (750 mg)
Salsalate, micro-crystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose in purified water. The granules were dried and mixed with croscarmellose sodium and colloidal silicon dioxide. The granules were lubricated with stearic acid. The lubricated mixture was compressed to provide tablets. The tablets were seal coated with a dispersion of hypromellose in purified water. The coated tablets were again coated with a dispersion of HPMC phthalate.
Dissolution profile for Tablets of Example 2:
Acid Phase: 0.1 N HCI / 900 ml/Apparatus I (Basket)/150 RPM
Buffer Phase: 0.25 M pH 7.4 Phosphate Buffer/900 mL/ Apparatus l(Basket)/150 RPM
Stability data for Tablets of Example 2:
Total Impurities
(Excluding Salicylic 0.0% 0.1 % 0.1 % 0.1 % Acid & Trisalicylic Acid)
The tablets of salsalate as per Example 2 were administered to healthy human volunteers in the form of tablets that contain 750 mg of salsalate each. These modified release compositions were administered to humans after a fasting period of at least about 8 hours. The blood samples were collected from each volunteer before administration and at several time points after administration (e.g., at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours). The plasma samples from each volunteer were assayed for salsalate and salicylic acid quantification using a validated method.
The tablets of Example 2 provided pharmacokinetic (PK) parameters substantially as shown in the below mentioned Table. These PK parameters are expressed as geometric mean (geometric CV %).
Example 3: Modified release tablets of salsalate (750 mq)
Lubrication
8 Stearic Acid (Stellipress Micro) 9.00 0.87
Seal Coating
9 Hypromellose 2910 5 cps (Methocel E5 LV) 14.25 1 .38
Polyethylene Glycol 8000 (Powder) (Carbowax
10 0.75 0.07
Sentry)
1 1 Ethanol* q.s.
12 Purified Water* q.s.
Functional Coating
13 Hypromellose Phthalate (HPMC HP 50) 76.50 7.43
Polyethylene Glycol 8000 (Powder) (Carbowax
14 8.50 0.83
Sentry
15 Ethanol* q.s.
16 Purified Water* q.s.
Flavor Coating
17 Opadry White 33F28398 27.00 2.62
18 Vanilla Flavor 3.00 0.29
19 Purified Water* q.s.
100.01
Total 1000.00
« 100.00
#-Does not remain in product except in traces.
Process:
Salsalate, microcrystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose in purified water. The granules were dried and mixed with croscarmellose sodium and colloidal silicon dioxide. The granules were lubricated with stearic acid. The lubricated mixture was compressed to provide tablets. The tablets were seal coated with a dispersion of hypromellose and polyethylene glycol in purified water and ethanol. The coated tablets were then functionally coated with a dispersion of HPMC phthalate and polyethylene glycol in purified water and ethanol. The coated tablets were then coated with a flavor coating of Opadry white and vanilla flavor in purified water.
Dissolution profile for Tablets of Example 3:
Acid Phase: 0.1 N HCI / 900 ml/Apparatus I (Basket)/150 RPM
Buffer Phase: 0.25 M pH 7.4 Phosphate Buffer/900 m L/ Apparatus l(Basket)/150 RPM
Stability data for Tablets of Example 3:
Example 4: Modified release capsules of salsalate (500 mq)
4 Hypromellose 2910 5 cps 24.00 3.43
5 Glycerin 2.00 0.29
6 Purified water q.s. —
Seal Coating
7 Hypromellose 2910 5 cps 14.25 2.04
8 Polyethylene glycol 8000 0.75 0.1 1
9 Purified water q.s. —
Functional coating
10 Acrylic acid copolymer 58.50 8.36
1 1 Polyethylene glycol 8000 6.50 0.93
12 Purified water q.s. —
Capsule filling
13 Size OO'el Hard Gelatin Capsule 1 # —
Total 700.00 100.00
Process:
Salsalate, microcrystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose and glycerin in purified water. The wet granules were extruded and spheronized to provide wet pellets. These pellets were dried and were seal coated with a dispersion of hypromellose in purified water. The coated pellets were again coated with a dispersion of acrylic acid copolymer. The final coated pellets were sized and filled into the capsules.
Dissolution profile for Capsules of Example 4:
6 30 94
7 45 97
8 60 94
Acid Phase: 0.1 N HCI / 900 ml/Apparatus I (Basket)/150 RPM
Buffer Phase: 0.25 M pH 7.4 Phosphate Buffer/900 m L/ Apparatus I (Basket)/150 RPM
Stability data for Capsules of Example 4:
Example 5: Modified release tablets of salsalate (500 mg)
7 Croscarmellose sodium 12.00 1 .75
Lubrication
8 Stearic acid 6.00 0.87
Seal coating
9 Hypromellose 2910 5 cps 9.50 1 .38
10 Polyethylene glycol 8000 0.50 0.07
1 1 Ethanol q.s.
12 Purified water q.s.
Functional coating
Hydroxypropyl methylcellulose
13 51 .00 7.43 phthalate (HPMCP)
14 Polyethylene glycol 8000 (Powder) 5.67 0.83
15 Ethanol q.s.
16 Purified water q.s.
Flavor coat
17 Opadry 18.00 2.62
18 Vanilla flavor 2.00 0.29
19 Purified water q.s.
Total 686.67 100.00
Process:
Salsalate, microcrystalline cellulose and croscarmellose sodium were mixed and granulated with a dispersion of hypromellose in purified water. The granules were dried and mixed with croscarmellose sodium and colloidal silicon dioxide. The granules were lubricated with stearic acid. The lubricated mixture was compressed to provide tablets. The tablets were seal coated with a dispersion of hypromellose in purified water. The coated tablets were again coated with a dispersion of HPMCP. The tablets were then coated with a flavor coat containing vanilla flavor.
Example 6
Process:
MR1 component:
Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The granules are extruded and spheronized to yield pellets. The MR1 pellets are dried to provide immediate release pellets of salsalate.
MR2 component:
Salsalate, micro-crystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The granules are extruded and spheronized to yield pellets. The pellets are dried and seal coated with a dispersion of hypromellose in purified water. The coated MR2 pellets are coated with a dispersion of methacrylic acid copolymer to provide modified release pellets of salsalate.
Capsules:
The MR1 pellets and MR2 pellets are mixed together along with micronized talc and filled in appropriate sized capsules.
In an alternative embodiment to Example 4, the capsules may be further coated with a modified release coating.
Example 7
Blending:
1 MR2 Component q.s.
2 MR1 Component q.s.
3 Stearic Acid 0.1 -5
Film Coating:
1 Opadry White 0.5-5
2 Purified Water q.s.
Process:
MR1 component:
Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The granules are extruded and spheronized to yield pellets. The pellets are dried and seal coated with a dispersion of hypromellose in purified water. The coated MR1 pellets are coated with a dispersion of methacrylic acid copolymer to provide modified release pellets of salsalate.
MR2 component:
Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The MR2 granules are dried to provide immediate release granules of salsalate.
Tablets:
The MR1 pellets and MR2 granules are mixed together along with stearic acid and compressed using appropriate tooling to yield tablets. These tablets are then film coated.
In an alternative embodiment to Example 5, the tablets may be further coated with a modified release coating.
Example 8
2 MR2 Component q.s.
3 MR3 Component q.s.
4 Micronized Talc 0.1 - 5
Process:
MR1 component
Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The granules are extruded and spheronized to yield pellets. The MR1 pellets are dried to provide immediate release pellets of salsalate.
MR2 component:
Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The granules are extruded and spheronized to yield pellets. The pellets are dried and seal coated with a dispersion of hypromellose in purified water. The coated MR2 pellets are coated with a dispersion of methacrylic acid copolymer to provide modified release pellets of salsalate.
MR3 component:
Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The granules are extruded and spheronized to yield pellets. The pellets are dried and seal coated with a dispersion of hypromellose in purified water. The coated MR3 pellets are coated with a dispersion of a different methacrylic acid copolymer than used in the MR2 component to provide modified release pellets of salsalate with a different release profile than of the MR2 pellets.
Capsules:
The MR1 pellets, MR2 pellets and MR3 pellets are mixed together along with micronized talc and filled in appropriate sized capsules.
In alternative embodiment to the capsules of Example 6, the capsules may be coated with a modified release coating.
Example 10
2 MR1 Component q.s.
3 MR2 Component q.s.
4 Stearic Acid 0.1 - 5
Film Coating:
1 Opadry White 0.5 - 5
2 Purified Water q.s.
Process:
MR1 component:
Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The granules are extruded and spheronized to yield pellets. The pellets are dried and seal coated with a dispersion of hypromellose in purified water. The coated MR1 pellets are coated with a dispersion of methacrylic acid copolymer to provide modified release pellets of salsalate.
MR2 component:
Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The granules are extruded and spheronized to yield pellets. The pellets are dried and seal coated with a dispersion of hypromellose in purified water. The coated MR2 pellets are coated with a dispersion of different type of methacrylic acid copolymer than used in the MR1 pellets to provide modified release pellets of salsalate with a different release profile than that of the MR1 pellets.
MR3 component:
Salsalate, microcrystalline cellulose and croscarmellose sodium are mixed and granulated with a dispersion of hypromellose in purified water. The granules are dried to provide immediate release MR3 granules of salsalate.
Tablets:
The MR1 pellets, MR2 pellets and MR3 granules are mixed together along with stearic acid and compressed using appropriate tooling to yield tablets. These tablets are film coated.
In an alternative embodiment to Example 9, the tablets may be further coated with a modified release coating.
Example 10
Salsalate Modified Release Tablets 750 mg (Fasting Study)
Pharmacokinetic Summary
A randomized, two-way, crossover study was conducted in 12 healthy adult human male volunteers out of whom 1 1 volunteers completed the study. The volunteers were administered one Salsalate Modified Release Tablets 750 mg (per Example 2) and Salsalate Tablets, USP 750 mg under fasted conditions in a crossover manner. The pharmacokinetic parameters of the parent compound (salsalate) and active metabolite (salicylic Acid) are summarized in below:
# Median (Range)
Compared to the immediate release formulation, there is little difference in mean Cmax value for the modified release formulation. However, the mean AUC0-t and AUCo-inf is decreased by approximately 13% and 5%, respectively in the modified release formulation. The median time-to-peak concentration (Tmax) is also delayed by 2.00 hours in the modified release formulation compared to the immediate release formulation (4.00 hours versus 2.00 hours). The mean half life of the immediate release and modified release formulations are very similar for salsalate.
Salicylic Acid
Pharmacokinetic Salsalate Modified Salsalate Tablets, USP Parameters Release Tablets (750 mg) 750 mg
Mean ± SD Mean ± SD
Cmax ^g/ml) 38.77 ± 17.47 51 .63 ± 7.56
AUCt ^g*hr/ml) 32.41 ± 17.1 1 440.22 ± 1 14.25
AUCi ^g*hr/ml) 333.36 ± 178.1 1 448.46 ± 122.52
Trnax* (hr) 5.50 (3.50, 9.00) 4.50 (3.00, 6.00)
Thalf (hr) 2.61 ± 0.87 2.57 ± 0.81
# Median (Range)
Compared to the immediate release formulation, the mean Cmax is decreased by 25% and both mean AUCo-t and AUCo-inf is decreased by approximately 26% in the modified release formulation. The median time-to-peak concentration (Tmax) is also delayed by 1 .00 hour in the modified release formulation as compared to the immediate release formulation (5.50 hours versus 4.50 hours). The mean half life of the immediate release and modified release formulations are very similar for salicylic acid.
Example 11
Calculation of dC/dT for Salsalate and Salicylic Acid
The change in concentration over time for salsalate and salicylic acid upon administration of 750 mg modified release salsalate tablets (per Example 2) are compared against 750 mg immediate release salsalate tablets. The results are provided below:
dC/dT Calculation-Salsalate
3 7.139 13.538 2.380 4.513 52.73
3.5 1 1 .097 10.095 3.171 2.884 109.93
4 9.935 6.984 2.484 1 .746 142.25
4.5 8.008 4.647 1 .780 1 .033 172.33
5 6.896 2.560 1 .379 0.512 269.38
5.5 6.657 1 .535 1 .210 0.279 433.68
6 5.158 0.977 0.860 0.163 527.94
6.5 3.900 0.653 0.600 0.100 597.24
7 2.961 0.442 0.423 0.063 669.91
7.5 1 .957 0.328 0.261 0.044 596.65
8 1 .368 0.217 0.171 0.027 630.41
9 0.556 0.067 0.062 0.007 829.85
10 0.262 0.029 0.026 0.003 903.45
1 1 0.120 0.018 0.01 1 0.002 666.67
12 0.050 0.013 0.004 0.001 384.62
14 0.018 0.000 0.001 0.000
16 0.000 0.000 0.000 0.000
18 0.000 0.000 0.000 0.000
24 0.000 0.000 0.000 0.000
48 0.000 0.000 0.000 0.000
96 0.000 0.000 0.000 0.000
The data above demonstrates that in a single dose human pharmacokinetic study of a modified release composition of salsalate, the composition provides a change in plasma concentration of salsalate as a function of time (dC/dT) over a defined period between 0 to 3 hours after administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over the defined time period. dC/dT Calculation-Salicylic Acid
4.00 24051 .818 48318.182 6012.955 12079.546 49.78
4.50 29324.364 51354.545 6516.525 1 1412.121 57.10
5.00 29810.000 46927.273 5962.000 9385.455 63.52
5.50 31605.000 44900.000 5746.364 8163.636 70.39
6.00 32510.727 42436.364 5418.455 7072.727 76.61
6.50 32445.909 40754.545 4991 .678 6269.930 79.61
7.00 32532.727 38045.455 4647.532 5435.065 85.51
7.50 31471 .818 35700.000 4196.242 4760.000 88.16
8.00 29852.727 32900.000 3731 .591 41 12.500 90.74
9.00 27007.273 28445.455 3000.808 3160.606 94.94
10.00 23739.909 24827.273 2373.991 2482.727 95.62
1 1 .00 20258.091 20715.455 1841 .645 1883.223 97.79
12.00 17468.909 17312.727 1455.742 1442.727 100.90
14.00 1 1688.182 1 1523.636 834.870 823.1 17 101.43
16.00 7642.636 7298.182 477.665 456.136 104.72
18.00 4729.909 4582.727 262.773 254.596 103.21
24.00 1 176.182 1029.000 49.008 42.875 114.30
48.00 0.000 0.000 0.000 0.000
96.00 0.000 0.000 0.000 0.000
The data above demonstrates that in a single dose human pharmacokinetic study of a modified release composition of salsalate, the composition provides a change in plasma concentration of salicylic acid as a function of time (dC/dT) over a defined period between 0 to 4 hours after administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over the defined time period.
While the invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the invention.
Claims
1 . A modified release pharmaceutical composition comprising salsalate or a pharmaceutically acceptable salt thereof, wherein the composition releases substantially no drug within the first two hours of its administration.
2. The modified release pharmaceutical composition of claim 1 , wherein the composition comprises about 100 mg to about 1000 mg of salsalate and provides an in-vivo plasma profile for salsalate when administered in a fasted state comprising: a mean of Cmax less than about 30 μg/mL,
a mean of AUC less than about 60 μg*hr/mL; and
a mean of Tmax at least about 2 hours.
3. The modified release pharmaceutical composition of claim 1 , wherein the composition comprises about 100 mg to about 1000 mg of salsalate and provides an in-vivo plasma profile for salicylic acid when administered in a fasted state comprising: a mean of Cmax less than about 55 μg/mL,
a mean of AUC less than about 500 μg*hr/mL; and
a mean of Tmax at least about 4.5 hours.
4. The modified release pharmaceutical composition of claim 1 , wherein the salsalate is present in an amount of at least 50% by weight of the total composition.
5. The modified release pharmaceutical composition according to claim 4, wherein the total weight of the composition is between 900 mg to 1500 mg, when the amount of salsalate in the composition is about 750 mg and between 550 mg to 1000 mg, when the amount of salsalate in the composition is about 500 mg.
6. The modified release pharmaceutical composition according to claim 1 , wherein the composition consists essentially of salsalate as the active ingredient and one or more enteric polymers and one or more pharmaceutically acceptable excipients.
7. The modified release pharmaceutical composition according to claim 6, wherein the enteric polymer is in a matrix with salsalate or coated on a core comprising salsalate.
8. The modified release pharmaceutical composition according to claim 6, wherein the composition further comprises an additional top coat of one or more flavoring agents.
9. The modified release pharmaceutical composition according to claim 6, wherein the composition is in the form of a tablet, a capsule, granules, powder, pellets, minitablets, microtablets, or a sachet.
10. The modified release pharmaceutical composition according to claim 6, wherein the pharmaceutically acceptable excipients comprise one or more of diluents, disintegrants, binders, stabilizers, buffering agents, lubricants, glidants, antiadherents, solubilizers, taste-masking agents, sweeteners, flavoring agents, and solvents.
1 1 . The modified release pharmaceutical composition according to claim 6, wherein the enteric polymer comprises one or more of hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, hydroxypropyl methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetate phthalate, polyvinyl butyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono-ester copolymer, carboxymethyl ethylcellulose, methyl methacrylate-methacrylic acid copolymer (Eudragit L-100 (methacrylic acid copolymer L) or Eudragit S-100 (methacrylic acid copolymer S)), methacrylic acid- ethyl acrylate copolymer (Eudragit L100-55 (dried methacrylic acid copolymer LD) or Eudragit L30D-55 (methacrylic acid copolymer LD)), methacrylic acid-methyl acrylate-methyl methacrylate copolymer (Eudragit FS30D), hydroxypropyl cellulose acetate succinate (HPMCAS), and shellac.
12. The modified release pharmaceutical composition according to claim 6, wherein the composition retains at least about 80% of the potency of salsalate in the pharmaceutical composition after storage for three months at 40°C and 75% relative humidity.
13. The modified release pharmaceutical composition according to claim 6, wherein the composition exhibits an in vitro dissolution profile, when measured in a USP dissolution apparatus type I, at 150 rpm, at a temperature of 37.0 ± 0.5°C in 900 ml of 0.1 N HCI for first two hours followed by measurement in pH 7.4 phosphate
buffer, such that at most 10% of salsalate is released in the first two hours and at least 80% of salsalate is released within the next two hours.
14. The pharmaceutical composition according to claim 1 , wherein the composition provides a change in plasma concentration of salsalate as a function of time (dC/dT) over a defined period between 0 and 3 hours after administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over said defined time period, wherein the dC/dT is measured in a single dose human pharmacokinetic study.
15. The pharmaceutical composition according to claim 1 , wherein the composition provides a change in plasma concentration of salicylic acid as a function of time (dC/dT) over a defined period between 0 and 4 hours after administration that is less than about 65% of the dC/dT of the same quantity of an immediate release form of salsalate over said defined time period, wherein the dC/dT is measured in a single dose human pharmacokinetic study.
16. The modified release pharmaceutical composition according to claim 1 made by a process comprising: i. mixing and/or granulating salsalate, one or more enteric polymers and one or more pharmaceutically acceptable excipients;
ii. compressing the mixture or granules to form a tablet; and
iii. optionally coating the tablet.
17. The modified release pharmaceutical composition according to claim 1 made by a process comprising: i. preparing a core comprising salsalate and one or more pharmaceutically acceptable excipients;
ii. optionally coating the core with an intermediate layer; and
iii. coating the core of step (i) or product of step (ii) with a layer comprising one or more enteric polymers.
18. The modified release pharmaceutical composition according to claim 1 made by a process comprising: i. preparing an inert core;
ii. coating the inert core with a solution / suspension comprising salsalate and one or more pharmaceutically acceptable excipients;
iii. coating the drug layered core of step (ii) with one or more enteric layers; and
iv. optionally coating the product of step (iii) with a functional / nonfunctional layer.
19. The modified release pharmaceutical composition according to claim 1 made by a process comprising: i. mixing and/or granulating salsalate with one or more pharmaceutically acceptable excipients;
ii. filling the mixture or granules into a capsule; and
iii. coating the capsule with an enteric coating.
20. A method for providing relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder in a patient in need thereof, comprising administering to the patient about 100 mg to about 1000 mg of salsalate in one or more modified release oral dosage forms, wherein the administering step provides a mean maximum plasma concentration (Cmax) less than 30 μg/mL of salsalate, a mean AUC less than about 60 μg*hr/mL and a mean Tmax of at least 2 hours to the patient.
21 . The method of claim 20, wherein at steady state the composition has a fluctuation index about 5-30% of a fluctuation index achieved with an immediate- release composition of the salsalate.
22. The method for claim 20, wherein the incidences of side effects associated with salsalate administration in immediate release form at the same strength is reduced.
23. A modified release pharmaceutical composition consisting essentially of 750 mg of salsalate or a pharmaceutically acceptable salt thereof as the only active ingredient in the composition, an enteric polymer to control the release of the salsalate from the composition based on a change in pH, and one or more pharmaceutical excipients, wherein the composition exhibits an in vitro dissolution profile, when measured in a USP dissolution apparatus type I, at 150 rpm, at a temperature of 37.0 ± 0.5 °C in 900 ml of 0.1 N HCIfor the first two hours followed by
measurement in pH 7.4 phosphate buffer, such that at most 10% of salsalate is released in the first two hours and at least 80% of salsalate is released within the next two hours.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361894277P | 2013-10-22 | 2013-10-22 | |
US61/894,277 | 2013-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015061442A1 true WO2015061442A1 (en) | 2015-04-30 |
Family
ID=52993500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/061760 WO2015061442A1 (en) | 2013-10-22 | 2014-10-22 | Delayed release pharmaceutical compositions of salsalate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015061442A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108329407A (en) * | 2017-12-28 | 2018-07-27 | 潍坊友容实业有限公司 | A method of extracting cellulose from Suaeda salsa |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138399A1 (en) * | 1999-05-14 | 2003-07-24 | Anton Peter A. | Anti-inflammatory therapy for inflammatory mediated infection |
US20070071820A1 (en) * | 2000-10-13 | 2007-03-29 | Euro-Celtique S.A. | Delayed release pharmaceutical formulations |
US20070092574A1 (en) * | 2003-07-23 | 2007-04-26 | Pr Pharmaceuticals, Inc. | Controlled released compositions |
US20090011013A1 (en) * | 2005-10-07 | 2009-01-08 | Lifecycle Pharma A/S | Tacrolimus Combination Products |
US20100015220A1 (en) * | 2008-05-20 | 2010-01-21 | Wetterau John R | Niacin and nsaid combination therapy |
US20100196472A1 (en) * | 2002-10-25 | 2010-08-05 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
US20120082634A1 (en) * | 2010-07-02 | 2012-04-05 | Solvotrin Therapeutics Ltd. | Treatment for dyslipidemia |
-
2014
- 2014-10-22 WO PCT/US2014/061760 patent/WO2015061442A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138399A1 (en) * | 1999-05-14 | 2003-07-24 | Anton Peter A. | Anti-inflammatory therapy for inflammatory mediated infection |
US20070071820A1 (en) * | 2000-10-13 | 2007-03-29 | Euro-Celtique S.A. | Delayed release pharmaceutical formulations |
US20100196472A1 (en) * | 2002-10-25 | 2010-08-05 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
US20070092574A1 (en) * | 2003-07-23 | 2007-04-26 | Pr Pharmaceuticals, Inc. | Controlled released compositions |
US20090011013A1 (en) * | 2005-10-07 | 2009-01-08 | Lifecycle Pharma A/S | Tacrolimus Combination Products |
US20100015220A1 (en) * | 2008-05-20 | 2010-01-21 | Wetterau John R | Niacin and nsaid combination therapy |
US20120082634A1 (en) * | 2010-07-02 | 2012-04-05 | Solvotrin Therapeutics Ltd. | Treatment for dyslipidemia |
Non-Patent Citations (1)
Title |
---|
PATEL ET AL.: "Formulation and evaluation of controlled porosity osmotic pump tablets of Glimepiride", INTERNATIONAL JOURNAL OF DRUG DELIVERY, vol. 4, no. 1, 2012, pages 113 - 124, Retrieved from the Internet <URL:http://www.arjournals.org/index.php/ijdd/index> [retrieved on 20150215] * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108329407A (en) * | 2017-12-28 | 2018-07-27 | 潍坊友容实业有限公司 | A method of extracting cellulose from Suaeda salsa |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101413613B1 (en) | A drug delivery system comprising a weakly basic selective serotonin 5-HT3 blocker and an organic acid | |
US20120128764A1 (en) | Controlled-release compositions comprising a proton pump inhibitor | |
US20140044784A1 (en) | Combined formulation with improved stability | |
US9642808B2 (en) | Extended release compositions comprising mycophenolate sodium and processes thereof | |
JP2011513391A (en) | Sustained release pharmaceutical composition containing mycophenolate and method thereof | |
CN109310642B (en) | Oral pharmaceutical composition of mesalamine | |
JP2015522653A (en) | Pharmaceutical composition of proton pump inhibitor | |
US20130143897A1 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
US20090208575A1 (en) | Pharmaceutical Composition Of Acid Labile Substances | |
CN109152772B (en) | Oral pharmaceutical composition of nicotinamide | |
WO2017084680A1 (en) | Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor | |
JP7581052B2 (en) | Oral coated tablet composition of lenalidomide | |
KR20190092805A (en) | Pharmaceutical composition comprising Acetylsalicylic acid and Lansoprazole | |
WO2022074681A1 (en) | Pharmaceutical compositions with enhanced blend uniformity and content uniformity | |
US11052048B2 (en) | Esomeprazole-containing complex capsule and preparation method therefor | |
US20150037408A1 (en) | Delayed Release Pharmaceutical Compositions of Salsalate | |
US20130202688A1 (en) | Delayed release oral disintegrating pharmaceutical compositions of lansoprazole | |
WO2015061442A1 (en) | Delayed release pharmaceutical compositions of salsalate | |
US20230364075A1 (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
US20110293713A1 (en) | Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs | |
AU2022346033A1 (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
US20040185092A1 (en) | Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use | |
MXPA00005895A (en) | Oral pharmaceutical pulsed release dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14856527 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14856527 Country of ref document: EP Kind code of ref document: A1 |